Novavax, Inc. announced that its 2024-2025 formula COVID-19 vaccine, Adjuvanted (NVX-CoV2705), is now available at major pharmacy retailers across the U.S. for individuals aged 12 and older. This updated vaccine aims to prevent COVID-19 and is the only protein-based option available in the U.S. this fall.
The vaccine is stocked at locations including CVS Pharmacy, Rite Aid, Walgreens, Costco, Publix, Sam’s Club, Kroger, Meijer, and thousands of independent pharmacies. The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for the vaccine on August 30, 2024.
Targeting Current Variants
According to Novavax President and CEO John C. Jacobs, the vaccine targets JN.1, the ‘parent strain’ of currently circulating variants, and has demonstrated cross-reactivity against JN.1 lineage viruses, including KP.2.3, KP.3, KP.3.1.1, and LB.1.1.
Vaccine Formulation and Availability
Novavax's vaccine is presented in a pre-filled syringe and is the only protein-based option available in the U.S. this fall. Doses can be located on us.novavaxcovidvaccine.com.
Important Safety Information
The Novavax COVID-19 Vaccine, Adjuvanted (2024-2025 Formula) has not been approved or licensed by the FDA but has been authorized for emergency use by the FDA, under an EUA to prevent Coronavirus Disease 2019 (COVID-19) for use in individuals 12 years of age and older. Refer to the full Fact Sheet for information about the Novavax COVID-19 Vaccine, Adjuvanted.
The EUA of this product will remain in effect for the duration of the COVID-19 EUA declaration justifying emergency use of the product, unless the authorization is revoked sooner.
Contraindications and Precautions
The vaccine should not be administered to individuals with a known history of severe allergic reaction (e.g., anaphylaxis) to any component of the Novavax COVID-19 Vaccine, Adjuvanted. Appropriate medical treatment must be immediately available to manage potential anaphylactic reactions following administration.
Clinical trials data provide evidence for increased risks of myocarditis and pericarditis following administration of Novavax COVID-19 Vaccine, Adjuvanted. Syncope (fainting) may occur in association with administration of injectable vaccines. Immunocompromised persons may have a diminished immune response to the vaccine. The Novavax COVID-19 Vaccine, Adjuvanted may not protect all vaccine recipients.
Adverse Reactions and Reporting
Solicited adverse reactions included injection site pain/tenderness, fatigue/malaise, muscle pain, headache, joint pain, nausea/vomiting, injection site redness, injection site swelling, and fever. The vaccination provider is responsible for mandatory reporting of certain adverse events to the Vaccine Adverse Event Reporting System (VAERS).
About the Vaccine
NVX-CoV2705 is an updated version of Novavax’s prototype COVID-19 vaccine (NVX-CoV2373) formulated to target the JN.1 variant. It is a protein-based vaccine made by creating copies of the surface spike protein of SARS-CoV-2 that causes COVID-19. The non-infectious spike protein serves as the antigen that primes the immune system to recognize the virus, while Novavax’s Matrix-M adjuvant enhances and broadens the immune response. The vaccine is packaged as a ready-to-use liquid formulation and is stored at 2° to 8°C.
